)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Nxera Pharma
Nxera Pharma (4565) investor relations material
Nxera Pharma Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary30 Oct, 2026
Executive summary
9M FY2026 revenue rose 27% to ¥27,742m; IFRS operating profit was ¥3,175m and net profit ¥2,328m, while core operating profit reached ¥9,818m.
Japan product sales and partner income supported growth; seven partnered molecules were in clinical trials, including two in Phase 3.
The model combines Japan commercialization, U.K. discovery and partner-funded global development; 2030 targets remain revenue above ¥50bn and operating margin above 30%.
Financial highlights
9M revenue was ¥27,742m, up 27%; partner revenue was ¥13,326m, up 63%, and commercial revenue was ¥14,416m, up 5%.
IFRS operating profit was ¥3,175m versus a ¥5,907m loss in 9M FY2025; core operating profit was ¥9,818m versus a ¥986m loss.
Core operating profit comprised ¥7,133m commercial and ¥2,685m platform; both were profitable.
R&D and SG&A declined 20% and 11% on a consolidated core basis; IFRS expenses were ¥8,951m and ¥8,330m, down ¥2,238m and ¥1,011m YoY.
IFRS results included ¥1,717m of impairment losses, including ¥1,114m goodwill impairment on the Sosei R&D acquisition; restructuring costs were ¥471m.
Outlook and guidance
FY2026 forecast remains unchanged: revenue ¥33,800m–¥48,800m, core operating profit ¥7,800m–¥22,800m and operating profit ¥700m–¥15,700m.
Product sales priority is at least ¥19.5bn for PIVLAZ and QUVIVIQ; 9M sales were ¥14.4bn, or 74% of target.
Forecast assumes ¥12,500m in partner milestones and ¥3,500m in R&D and SG&A cost-base reductions; lower-end ranges assume no significant new business-development deals.
2030 targets are revenue above ¥50bn, operating margin above 30% and more than five Japan products; the 2035 margin target is ~40%.
Expected catalysts include Direclidine Phase 3 and ORX750 Phase 2/3 data in H2 2027, an AGAMREE Japan filing in H2 2027, and a lucerastat global NDA as early as 2029, subject to results and approval.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Nxera Pharma
- Acquisition-driven expansion sets up PIVLAZ growth and heavier FY2024 investment.4565
Q4 2023 - Revenue up 25.3% YoY, profitability restored, and strong growth in key products and partnerships.4565Q2 2026
- Obesity pipeline advances, commercial growth, and AI-driven discovery fuel strategic momentum.4565Jefferies Global Healthcare Conference 2026
- Q1 2026 saw a sharp turnaround to profit, fueled by milestone revenues and product growth.4565Q1 2026
- Strong pipeline, commercial growth, and 2026 profitability focus drive future value.4565Corporate presentation
- Revenue up, net loss widens; restructuring and new deals target FY2026 profitability.4565Q4 2025
- Restructuring and R&D focus drive growth, cost savings, and innovation in key markets.4565R&D Day
- Revenue and profit surged on PIVLAZ sales, partnerships, and milestones; outlook remains strong.4565Q2 2024
- Revenue up 126% YoY to JPY 28.8bn, with profit outlook tied to milestone income.4565Q1 2025
Next Nxera Pharma earnings date
Jefferies Global Healthcare Conference16 Nov, 2026
Nxera Pharma
Next Nxera Pharma earnings date
Jefferies Global Healthcare Conference16 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Sosei Group Corporation, also known as Sosei Heptares, is a biopharmaceutical company that specializes in the development of drugs using its proprietary G protein-coupled receptor (GPCR) targeted StaR technology and structure-based drug discovery (SBDD) platform. The company's product lineup includes medicines such as Ultibro, Seebri, Enerzair, Breezhaler, Pivlaz, and Oravi. Sosei Group Corporation is headquartered in Chiyoda-ku, Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.